Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Biogen Idec's long-acting beta interferon moves ahead in MS
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Rituximab in paediatric onset multiple sclerosis: a case series.
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
The challenge of comorbidity in clinical trials for multiple sclerosis.
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Spin-offs: Meet the structure specialists

Pages